Moore, P.A., Shah, K., Yang, Y., Alderson, R., Roberts, P., Long, V., Liu, D., Li, J.C., Burke, S., Ciccarone, V., Li, H., Fieger, C.B., Hooley, J., Easton, A., Licea, M., Gorlatov, S., King, K.L., Young, P., Adami, A., Loo, D., Chichili, G.R., Liu, L., Smith, D.H., Brown, J.G., Chen, F.Z., Koenig, S., Mather, J., Bonvini, E. and Johnson, S. (2018) Development of MGD007, a gpA33 × CD3-Bispecific DART Protein for T-Cell Immuno-therapy of Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 17, 1761-1772.
https://doi.org/10.1158/1535-7163.MCT-17-1086

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.